2023
Multimodality Neuroimaging Biomarkers in Parkinson’s Disease
Zhang X, Mohan V, Wooten D, Hooker B, Zhuang Y, Honhar P, Holmes S, Naganawa M, Dias M, Comley R, Carson R, Tinaz S, Matuskey D, Luo Y, Finnema S. Multimodality Neuroimaging Biomarkers in Parkinson’s Disease. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/2279.Peer-Reviewed Original Research
2011
Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients
Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K. Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients. PLOS ONE 2011, 6: e17338. PMID: 21386999, PMCID: PMC3046146, DOI: 10.1371/journal.pone.0017338.Peer-Reviewed Original ResearchConceptsDrug-naïve patientsDrug-naïve PD patientsPositron emission tomographyPD patientsParkinson's diseaseAntiparkinsonian therapyControl subjectsAffected sideDisease patientsCaudate nucleusParkinson's disease patientsElderly control subjectsNormal control subjectsSelective A2AR antagonistAdenosine A2A receptorsDistribution volume ratioMild dyskinesiaA2AR antagonistDopaminergic systemBilateral putamenPET scansPatientsA2A receptorsNovel treatmentsPutamen